Morishita Jintan Co., Ltd.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Dividend History 4Years Growth
Updated 2026/08/23| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥65 | +18.2% |
| 2025 | ¥55 | +10.0% |
| 2024 | ¥50 | +25.0% |
| 2023 | ¥40 | +6.7% |
| 2022 | ¥38 | - |
Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥11,359M | ¥12,406M | ¥12,766M | ¥12,688M |
| Gross Profit | ¥5,311M | ¥5,997M | ¥5,973M | ¥6,094M |
| Operating Income | ¥574M | ¥720M | ¥809M | ¥697M |
| Pretax Income | ¥625M | ¥822M | ¥780M | ¥795M |
| Net Income | ¥491M | ¥697M | ¥547M | ¥628M |
| EPS | ¥120.55 | ¥170.68 | ¥133.78 | ¥153.53 |
| Operating Margin | 5.05% | 5.80% | 6.34% | 5.49% |
| Balance Sheet | ||||
| Total Assets | ¥16,103M | ¥17,183M | ¥17,896M | ¥18,623M |
| Total Equity | ¥11,391M | ¥12,143M | ¥12,152M | ¥12,976M |
| Total Liabilities | ¥4,712M | ¥5,040M | ¥5,744M | ¥5,647M |
| Cash | ¥2,409M | ¥1,092M | ¥1,940M | ¥1,828M |
| Interest-bearing Debt | ¥537M | ¥425M | ¥1,457M | ¥1,834M |
| Equity Ratio | 70.74% | 70.67% | 67.90% | 69.68% |
| D/E Ratio | 0.05 | 0.03 | 0.12 | 0.14 |
| Cash Flow | ||||
| Operating CF | ¥1,179M | ¥196M | ¥669M | ¥1,150M |
| Investing CF | -¥474M | -¥1,152M | -¥701M | -¥1,232M |
| Financing CF | -¥433M | -¥362M | ¥880M | -¥30M |
| Free CF | ¥715M | -¥455M | -¥10M | -¥77M |
| Efficiency | ||||
| ROE | 4.31% | 5.74% | 4.50% | 4.84% |
| ROA | 3.05% | 4.06% | 3.06% | 3.37% |
Latest IR Information
-
Morishita Nendan Co., Ltd. Q1 Financial Summary (Consolidated) [Japanese GAAP]
For the cumulative first quarter, net sales were 3,476 million yen (YoY +4.0%), operating income was 417 million yen (+115.0%), ordinary income was 436 million yen (+108.5%), and net income attributable to owners of the parent was 324 million yen...
Read more -
【Morishita Taizan】2024 Financial Results | Revenue Unknown (YoY Unknown)
The financial results for Morishita Taizan for April of Reiwa 8 have been finalized. While the details of revenue and net profit are unknown, revenue is unspecified, and net profit is unspecified. Reporting the parent company's financial results.
Read more -
Completion of Treasury Stock Disposition with Restricted Stock Compensation | July 24, 2026
Morishita Jintan disposed of 8,700 shares of treasury stock on July 24, 2026, raising a total of 18,705,000 yen. The recipients were 2 directors and 4 executive officers, with a disposal price of 2,150 yen per share.
Read more -
Notice Regarding the Disposal of Treasury Shares as Restricted Stock Compensation
Read more -
Matters Concerning Controlling Shareholders, etc.
Read more
Latest News (5 items)
Company Information
About
Morishita Jintan Co., Ltd. manufactures and sale of pharmaceuticals, quasi-drugs, and health food in Japan. The company offers health food products, oral care products, and medical supplies under the JINTAN brand. It also sells health food, medicines, food, and miscellaneous goods, as well as other company's products through phone/postcard/online shops; cosmetics, domestic products through department stores, drugstores, convenience stores, volume sellers, and supermarkets; and BabyD 200, Bifidus HD, and Bifidobacterium Pearl products through medical institutions. In addition, the company offers OEM contract of supplements services. Further, it develops Jintan capsule technology that allows encapsulating various contents, such as powder, liquid, microbe or others. Morishita Jintan Co., Ltd. was founded in 1893 and is headquartered in Chuo, Japan.
